AbbVie key statistics and ratios

In fiscal 2025, AbbVie had an operating margin of 24.6% and a current ratio of 0.67. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

AbbVie: financial ratios, annual
Fiscal year	2011Dec 2011	2012Dec 2012	2013Dec 2013	2014Dec 2014	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMSept 2026
Gross margin	—	—	—	—	—	77.3%	75.0%	76.4%	77.6%	66.4%	69.0%	70.0%	62.4%	70.0%	70.2%	73.7%
Operating margin	20.8%	31.6%	30.1%	17.1%	33.0%	36.4%	33.8%	19.5%	39.0%	24.8%	31.9%	31.2%	23.5%	16.2%	24.6%	32.2%
Net margin	19.7%	28.7%	22.0%	8.9%	22.5%	23.2%	18.8%	17.4%	23.7%	10.1%	20.5%	20.4%	9.0%	7.6%	6.9%	15.7%
Free-cash-flow margin	33.8%	32.7%	30.7%	14.7%	30.6%	25.6%	33.4%	39.0%	38.4%	36.7%	39.1%	41.8%	40.6%	31.7%	29.1%	28.6%
Return on equity	—	—	199.3%	56.9%	180.9%	138.7%	109.1%	—	—	188.3%	81.0%	72.5%	35.2%	62.5%	—	—
Return on assets	—	19.5%	14.7%	6.3%	12.8%	10.0%	7.8%	8.7%	10.6%	3.9%	7.8%	8.3%	3.6%	3.2%	3.1%	7.3%
Asset turnover	—	0.68	0.67	0.70	0.57	0.43	0.41	0.50	0.45	0.38	0.38	0.41	0.40	0.42	0.45	0.47
Current ratio	—	2.27	2.59	1.41	1.50	1.65	1.28	0.98	3.18	0.84	0.79	0.96	0.87	0.66	0.67	0.87
Debt to equity	—	—	327.8%	859.8%	802.8%	794.7%	733.1%	—	—	658.1%	497.7%	366.7%	573.2%	>999%	—	—
Interest cover (operating income ÷ interest)	—	55.9x	18.9x	8.0x	10.5x	8.9x	8.3x	4.7x	7.3x	4.6x	7.4x	8.1x	5.7x	3.3x	5.2x	7.1x
Effective tax rate	6.4%	7.9%	22.6%	25.1%	22.6%	24.5%	31.3%	−9.4%	6.5%	−36.0%	11.1%	12.1%	22.0%	−15.3%	35.8%	19.2%
R&D as % of revenue	15.0%	15.1%	15.2%	16.5%	18.7%	17.1%	17.7%	31.5%	19.3%	13.9%	12.3%	11.2%	14.1%	22.7%	14.9%	15.1%
SG&A as % of revenue	33.8%	27.1%	28.5%	38.7%	27.9%	22.9%	22.3%	22.6%	20.9%	24.7%	22.0%	26.3%	23.7%	26.2%	22.9%	23.0%
Capital spending as % of revenue	2.0%	1.8%	2.6%	3.1%	2.3%	1.9%	1.9%	1.9%	1.7%	1.7%	1.4%	1.2%	1.4%	1.7%	2.0%	1.8%
Free cash flow ÷ net income	171.6%	114.0%	139.9%	165.6%	136.1%	110.2%	177.6%	224.9%	162.0%	363.7%	190.5%	204.9%	453.7%	416.8%	421.6%	182.5%
Dividends ÷ net income	—	—	61.9%	150.0%	64.0%	62.4%	77.4%	98.1%	80.8%	167.2%	80.2%	84.9%	216.7%	257.7%	275.8%	117.4%
Dividends and buybacks ÷ free cash flow	—	—	49.8%	113.2%	155.4%	148.6%	58.5%	137.6%	54.8%	51.8%	46.4%	47.6%	56.7%	71.4%	70.9%	72.3%

US$ thousands unless shown otherwise. Fiscal quarters.

AbbVie: financial ratios, quarterly
Quarter	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026	2026 Q3Sept 2026
Gross margin	70.9%	70.0%	71.8%	66.4%	72.6%	71.9%	74.7%	75.4%
Operating margin	−9.9%	28.0%	31.7%	12.1%	27.3%	26.6%	37.9%	36.0%
Net margin	−0.1%	9.6%	6.1%	1.2%	10.9%	4.6%	21.3%	24.2%
Free-cash-flow margin	44.7%	10.5%	31.7%	42.1%	29.4%	23.8%	18.3%	42.0%
Current ratio	0.66	0.76	0.74	0.72	0.67	0.80	0.81	0.87
Debt to equity	>999%	>999%	—	—	—	—	—	—
R&D as % of revenue	44.9%	15.5%	13.8%	14.7%	15.5%	16.5%	13.8%	14.7%
SG&A as % of revenue	25.5%	24.7%	21.1%	22.6%	23.4%	23.9%	21.4%	23.5%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

2 of 4 checks passed · September 30, 2026

What it owns · $147.7bn

Short-term assets $37.5bnLonger-term assets $110.2bn

What it owes, and who funded it · $43.1bn

Short-term liabilities $43.1bnShareholders' equity $-4.6bn

Short-term assets cover short-term liabilities $37.5bn of assets due within a year against $43.1bn of liabilities due within a year.
Short-term assets cover long-term liabilities Not assessable from the reported split. Not assessable.
More cash than debt $10.8bn of cash against $72.2bn of debt.
Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
A year's operating cash flow covers at least 20% of debt $20.1bn of operating cash flow against $72.2bn of debt.
Operating profit covers interest at least five times over Operating income of $21.2bn against $3.0bn of interest.

From AbbVie's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

87 /100

Strong moat

How hard AbbVie's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

Returns on capital 20 / 20

Cash operating profit has been a median 21.0% of total assets over 10 years.
Pricing power 18 / 20

Gross margin has been a median 69.7%, moving by 4.0 percentage points (standard deviation) across 10 years.
Durability 17 / 20

Operating margin has been a median 29.3%; its worst year was 15.2%.
Cash conversion 20 / 20

Free cash flow was positive in 10 of 10 years, at a median 37.4% of revenue.
Discipline 17 / 20

The diluted share count fell 0.3% over five years; stock-based pay has been a median 1.3% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (92 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: ABBV vs AMGN ABBV vs GILD ABBV vs REGN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from AbbVie's SEC filings (10-K and 10-Q), retrieved November 3, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to AbbVie.